Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials.

Saved in:
Bibliographic Details
Title: Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials.
Authors: Kim BS; Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Gonçalo M; Department of Dermatology, Hospital da Universidade, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.; Clinic of Dermatology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal., Ugajin T; Department of Dermatology, Institute of Science Tokyo, Tokyo, Japan., Gao XH; The First Hospital of China Medical University, Shenyang, China., Praestgaard AH; Sanofi, Cambridge, MA, USA., Makhija M; Sanofi, Cambridge, MA, USA., Zahn J; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Bansal A; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Wiggins S; Sanofi, 410 Thames Valley Park Drive, Reading, RG6 1PT, UK. Simmi.Wiggins@sanofi.com.
Source: American journal of clinical dermatology [Am J Clin Dermatol] 2026 Jan; Vol. 27 (1), pp. 167-180. Date of Electronic Publication: 2025 Nov 11.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100895290 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1888 (Electronic) Linking ISSN: 11750561 NLM ISO Abbreviation: Am J Clin Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1179-1888
DOI:10.1007/s40257-025-00993-1